Varenicline for smoking cessation

References

• Tobacco control: strengthening national efforts. In: The World Health Report 2003: Shaping the Future. World Health Organization, Geneva, Switzerland, 91–95 (2003).
   Google Scholar
• Vollset SE, Tverdal A, Gjessing HK. Smoking and deaths between 40 and 70 years of age in women and men. Ann. Intern. Med.144, 381–389 (2006).
   PubMed Web of Science ®Google Scholar
• Tonstad S. Analyzing the benefits and risks of tobacco cessation treatments. J. Clin. Psychiatry Monograph.18, 41–49 (2003).
   Google Scholar
• Fiore MC, Bailey WC, Cohen SJ et al. Treating Tobacco Use and Dependence: Clinical Practice Guidelines. US Department of Health and Human Services, Public Health Service, MD, USA (2000).
   Google Scholar
• National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy and bupropion for smoking cessation. NICE technology appraisal no. 39. NICE, London, UK (2002).
   Google Scholar
• Silagy C, Lancaster T, Stead L et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev.3, CD000146 (2004).
   Google Scholar
• Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev.4, CD000031 (2004).
   Google Scholar
• Nides M, Oncken C, Gonzales D et al; for the Varenicline study group. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist. Arch. Intern. Med.166, 1561–1568 (2006).
   PubMed Web of Science ®Google Scholar
• Oncken C, Gonzales D, Nides M et al; for the Varenicline study group. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med.166, 1571–1577 (1006).
   Google Scholar
• Gonzales D, Rennard SI, Nides M et al; for the Varenicline Phase 3 study group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA296(1), 47–55 (2006).
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA et al; for the Varenicline Phase 3 study group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA, 296(1), 56–63 (2006).
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tønnesen P, Hajek P et al; for the Varenicline phase 3 study group. Effect of maintenance therapy with varenicline on smoking cessation. A randomized controlled trial. JAMA,296(1), 64–71 (2006).
   PubMed Web of Science ®Google Scholar
• Coe JW, Brooks PR, Vetelino MG et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem.48, 3474–3477 (2005).
   PubMed Web of Science ®Google Scholar
• Rollema H, Chambers LK, Coe JW et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology (2006) (In Press).
   PubMedGoogle Scholar
• Obach RS, Reed-Hagen AE, Krueger SS et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab. Dispos.34, 121–130 (2006).
   PubMed Web of Science ®Google Scholar
• Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J. Clin. Pharmacol.46(9), 991–998 (2006).
   PubMed Web of Science ®Google Scholar
• Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J. Clin. Pharmacol.46(12), 1439–1448 (2006).
   PubMed Web of Science ®Google Scholar
• Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int. J. Clin. Pract.60(5), 571–576 (2006).
   PubMed Web of Science ®Google Scholar
• Sallette J, Pons S, Devillers-Thiery A et al. Nicotine upregulates its own receptors through enhanced intracellular maturation. Neuron46, 595–607 (2005).
   PubMed Web of Science ®Google Scholar
• Picciotto MR, Zoli M, Changeux JP. Use of knockout mice to determine the molecular basis for the actions of nicotine. Nicotine & Tob. Res.1(Suppl. 2), S121–S125 (1999).
   Google Scholar
• Tapper AR, McKinney SL, Nashmi R et al. Nicotine activation of α4 receptors: sufficient for reward, tolerance, and sensitization. Science306, 1029–1032 (2004).
   PubMed Web of Science ®Google Scholar
• Mihalak KB, Carroll I, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol. Pharm.70(3), 801–805 (2006).
   PubMed Web of Science ®Google Scholar
• Burstein A, Fullerton T, Clark D, Faessel HM. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J. Clin. Pharmacol.46(11), 1234–1240 (2006).
   PubMed Web of Science ®Google Scholar
• Hays JT, Hurt RD, Rigotti NA et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. Ann. Intern. Med.135, 423–433 (2001).
   PubMed Web of Science ®Google Scholar
• Hajek P, Stead LF, West R et al. Relapse prevention interventions for smoking cessation. Cochrane Database Syst. Rev.1, CD003999 (2005).
   Google Scholar
• Reeves K, Watsky E, Williams K et al. The safety of varenicline taken for 52 weeks for smoking cessation. Presented at: Society for Research on Nicotine and Tobacco 12th Annual Meeting. Orlando, FL, USA 15–18 February 2006.
   Google Scholar
• Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict. Biol.10(3), 219–231 (2005).
   PubMed Web of Science ®Google Scholar
• Anthenelli R, Dale L. Rimonabant helps cigarette smokers stop smoking and prevents post cessation weight gain: results from the STRATUS-US trial. In: Final Program and abstracts of 6th Annual Conference of the SRNT Europe. Tubingen, Germany, 35 (2004).
   Google Scholar
• Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin. Investig. Drug15, 107–116 (2006).
   PubMed Web of Science ®Google Scholar
• Hogg RC, Bertrand D. Nicotinic receptors as drug targets. Curr. Drug Targets CNS Neurol Disord.3, 123–130 (2004).
   PubMedGoogle Scholar
• Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alc. Rev.25, 59–71 (2006).
   PubMed Web of Science ®Google Scholar